School of Medicine, Western Sydney University, Campbelltown, NSW, Australia.
St George and Sutherland Clinical Campus, School of Clinical Medicine, Faculty of Medicine and Health, UNSW, Sydney, Australia; UNSW Microbiome Research Centre, St George and Sutherland Clinical School, UNSW, Sydney, Australia; Department of Gastroenterology and Hepatology, St George Hospital, Sydney, Australia.
Prog Neuropsychopharmacol Biol Psychiatry. 2024 Jul 13;133:111014. doi: 10.1016/j.pnpbp.2024.111014. Epub 2024 Apr 20.
Cocaine use disorder (CUD) is a global health problem with no approved medications. One potential treatment target is the gut microbiome, but it is unknown if cocaine induces long-lasting effects on gut microbes. A novel therapeutic candidate for CUD, cannabidiol (CBD), can improve gut function in rodent models. It is possible that protective effects of CBD against cocaine use are mediated by improving gut health. We examined this question in this experiment. Cocaine conditioned place preference (CPP) was conducted in adult male C57BL/6JArc mice. Mice were treated with vehicle or 20 mg/kg CBD prior to all cocaine CPP sessions (N = 11-13/group). Mice were tested drug free 1, 14 and 28 days after cessation of cocaine and CBD treatment. Fecal samples were collected prior to drug treatment and after each test session. Gut microbiome analyses were conducted using 16 s rRNA sequencing and correlated with behavioural parameters. We found a persistent preference for a cocaine-environment in mice, and long-lasting changes to gut microbe alpha diversity. Cocaine caused persistent changes to beta diversity which lasted for 4 weeks. CBD treatment reduced cocaine-environment preference during abstinence from cocaine and returned gut beta diversity measures to control levels. CBD treatment increased the relative abundance of Firmicutes phyla and Oscillospira genus, but decreased Bacteroidetes phyla and Bacteroides acidifaciens species. Preference score in cocaine-treated mice was positively correlated with abundance of Actinobacteria, whereas in mice treated with CBD and cocaine, the preference score was negatively correlated with Tenericutes abundance. Here we show that CBD facilitates cocaine extinction memory and reverses persistent cocaine-induced changes to gut microbe diversity. Furthermore, CBD increases the abundance of gut microbes which have anti-inflammatory properties. This suggests that CBD may act via the gut to reduce the memory of cocaine reward. Our data suggest that improving gut health and using CBD could limit cocaine abuse.
可卡因使用障碍(CUD)是一个全球性的健康问题,目前尚无批准的药物。一个潜在的治疗靶点是肠道微生物组,但可卡因是否会对肠道微生物产生持久影响尚不清楚。大麻二酚(CBD)是一种治疗 CUD 的新型治疗候选药物,它可以改善啮齿动物模型的肠道功能。CBD 对可卡因使用的保护作用可能是通过改善肠道健康来介导的。在本实验中,我们研究了这个问题。在成年雄性 C57BL/6JArc 小鼠中进行可卡因条件性位置偏好(CPP)。在所有可卡因 CPP 疗程之前,小鼠接受载体或 20mg/kg CBD 治疗(每组 11-13 只)。在停止可卡因和 CBD 治疗后 1、14 和 28 天,对小鼠进行无药物测试。在药物治疗前和每次测试后收集粪便样本。使用 16s rRNA 测序进行肠道微生物组分析,并与行为参数相关联。我们发现,在小鼠中存在持久的可卡因环境偏好,以及肠道微生物 alpha 多样性的持久变化。可卡因引起的 beta 多样性变化持续了 4 周。CBD 治疗可减少可卡因戒断期间对可卡因环境的偏好,并使肠道 beta 多样性测量值恢复到对照水平。CBD 治疗增加了厚壁菌门和 Oscillospira 属的相对丰度,但减少了拟杆菌门和 Bacteroides acidifaciens 种的相对丰度。可卡因处理小鼠的偏好评分与放线菌的丰度呈正相关,而在接受 CBD 和可卡因治疗的小鼠中,偏好评分与 Tenericutes 的丰度呈负相关。在这里,我们表明 CBD 促进可卡因的灭绝记忆,并逆转了可卡因引起的肠道微生物多样性的持久变化。此外,CBD 增加了具有抗炎特性的肠道微生物的丰度。这表明 CBD 可能通过肠道来减少可卡因奖励的记忆。我们的数据表明,改善肠道健康和使用 CBD 可能限制可卡因滥用。